Abstract 529P
Background
Ramucirumab (RAM) plus docetaxel (DOC) combination therapy is one of the standard treatment options for second-line in patients with advanced NSCLC. Previous studies reported that history of pre-administration of immune checkpoint inhibitors was related to good outcomes with RAM plus DOC. However, the clinical significance of RAM plus DOC after combined immunotherapy is little known. Therefore, we evaluated RAM plus DOC after combined chemoimmunotherapy and attempted to identify predictors for their outcomes.
Methods
This multicenter prospective study aimed to investigate the efficacy and safety of RAM plus DOC after combined chemoimmunotherapy. The primary endpoint was progression-free survival (PFS). The secondary endpoints are objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence of adverse events (AEs). Serum cytokines at the start of treatment were measured as an exploratory investigation.
Results
A total of 44 patients were enrolled, at 10 Japanese institutions from November 2019 and March 2021. The median PFS was 6.3 months (95% confidence interval [CI]: 4.2–8.8), and the median OS was 22.6 months (95% CI: 13.9–NE). The ORR and DCR were 36.4% (95% CI: 22.4–52.2) and 72.7% (95% CI: 57.2–85.0). High VEGF-D groups had significantly shortened PFS and OS. The combination of high VEGF-A and low VEGF-D had a longer PFS than other groups.
Conclusions
The primary endpoint was met; RAM plus DOC after combined chemoimmunotherapy is an effective and relatively feasible second-line treatment in patients with advanced NSCLC in the real-world setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Yamada, K. Takayama: Financial Interests, Personal, Invited Speaker: Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract